Loading...
Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: An individual patient-level analysis of double-blind randomized trials
Author
Cleland, John G. F.
Bunting, Karina V.
Flather, Marcus D.
Altman, Douglas G.
Holmes, Jane
Coats, Andrew J. S.
Manzano, Luis
McMurray, John J. V.
Ruschitzka, Frank
van Veldhuisen, Dirk J.
von Lueder, Thomas G.
Böhm, Michael
Andersson, Bert
Kjekshus, John
Packer, Milton
Rigby, Alan S.
Rosano, Giuseppe
Wedel, Hans
Hjalmarson, Åke
Wikstrand, John
Kotecha, Dipak
Bunting, Karina V.
Flather, Marcus D.
Altman, Douglas G.
Holmes, Jane
Coats, Andrew J. S.
Manzano, Luis
McMurray, John J. V.
Ruschitzka, Frank
van Veldhuisen, Dirk J.
von Lueder, Thomas G.
Böhm, Michael
Andersson, Bert
Kjekshus, John
Packer, Milton
Rigby, Alan S.
Rosano, Giuseppe
Wedel, Hans
Hjalmarson, Åke
Wikstrand, John
Kotecha, Dipak
Principal Supervisor
Co-Supervisor
Degree Name
Abstract
Aims: Recent guidelines recommend that patients with heart failure and left ventricular ejection fraction (LVEF) 40–49% should be managed similar to LVEF ≥ 50%. We investigated the effect of beta-blockers according to LVEF in double-blind, randomized, placebo-controlled trials. Methods and results: Individual patient data meta-analysis of 11 trials, stratified by baseline LVEF and heart rhythm (Clinicaltrials.gov: NCT0083244; PROSPERO: CRD42014010012). Primary outcomes were all-cause mortality and cardiovascular death over 1.3 years median follow-up, with an intention-to-treat analysis. For 14 262 patients in sinus rhythm, median LVEF was 27% (interquartile range 21–33%), including 575 patients with LVEF 40–49% and 244 ≥ 50%. Beta-blockers reduced all-cause and cardiovascular mortality compared to placebo in sinus rhythm, an effect that was consistent across LVEF strata, except for those in the small subgroup with LVEF ≥ 50%. For LVEF 40–49%, death occurred in 21/292 [7.2%] randomized to beta-blockers compared to 35/283 [12.4%] with placebo; adjusted hazard ratio (HR) 0.59 [95% confidence interval (CI) 0.34–1.03]. Cardiovascular death occurred in 13/292 [4.5%] with beta-blockers and 26/283 [9.2%] with placebo; adjusted HR 0.48 (95% CI 0.24–0.97). Over a median of 1.0 years following randomization (n = 4601), LVEF increased with beta-blockers in all groups in sinus rhythm except LVEF ≥50%. For patients in atrial fibrillation at baseline (n = 3050), beta-blockers increased LVEF when < 50% at baseline, but did not improve prognosis. Conclusion: Beta-blockers improve LVEF and prognosis for patients with heart failure in sinus rhythm with a reduced LVEF. The data are most robust for LVEF < 40%, but similar benefit was observed in the subgroup of patients with LVEF 40–49%.
Keywords
heart failure, ejection fraction, beta-blockers, mortality, sinus rhythm, atrial fibrillation
Publication Date
2018
Type
Journal article
Published In
European Heart Journal
Volume
39
Issue
1
Article Number
Start page
End page
Page Range
26-35
ACU Organisational Area
Collections
ACU Research Bank Link
Related
Open Access Status
File Access
Controlled
